Neuromuscular Blockade in Severe ARDS: Continuous Strategy or a Bolus Timed to the Turn
A single patient, one hour from being turned prone in severe ARDS. Two trials, fifteen years apart, enrolled the same severity band and disagreed — and the team has to decide tonight whether either of them was studying the patient in front of them.
R.D. runs a four-man roofing crew and, by his wife's account when she called this morning, had not missed a day of work sick in eleven years before this one. Four days ago he came down with fever and a cough his crew assumed was ordinary flu; two days ago he could not finish a sentence without stopping to breathe, and yesterday afternoon he was intubated in the emergency department for refractory hypoxemia despite high-flow oxygen — his chest X-ray on arrival already showing the bilateral infiltrates that would meet ARDS criteria within hours of admission. He is otherwise unremarkable for a 52-year-old in his line of work: overweight at roughly 245 pounds, hypertension controlled on lisinopril, no diabetes, no prior lung disease, and until this week no reason for anyone to think twice about his baseline health.
Tonight his PaO2/FiO2 ratio sits at 118 on FiO2 0.8 and PEEP 14 — and the exact number matters more here than the severity label does. ACURASYS (Papazian, 2010), the trial most clinicians reach for when this question comes up, enrolled down to a P/F of 150, but its adjusted 90-day mortality benefit concentrated in the patients below 120. At 118 he is inside the narrower band where the effect was actually measured, not merely inside the door the trial left open. His plateau pressure is sitting right at 30 cmH2O, the upper edge of what lung-protective ventilation tolerates before its own benefit erodes, and despite deep sedation he is fighting the ventilator hard enough that the respiratory therapist has twice had to hand-bag him back into synchrony, each episode dropping his saturation into the mid-80s before recovering. His weight matters practically as well as physiologically — any neuromuscular blocker dosed tonight has to be dosed off his actual body weight, not an estimate, given how close his oxygenation reserve already is to the edge. He is being proned this shift. ROSE, the trial usually raised against ACURASYS, randomized its control arm to a light-sedation strategy that reached for paralysis only as rescue — and light sedation is precisely the arm he has already failed, hand-bagged back into synchrony twice tonight on sedation that is already deep. Whatever the two trials say about severe ARDS in general, he has already left the comparison ROSE was built to test.
Before the turn, deciding how far to commit
I'd start a continuous cisatracurium infusion now, before we prone him, and run it the full forty-eight hours the way ACURASYS actually tested it. His P/F ratio of 118 puts him below 120, and that distinction matters: 150 was ACURASYS's enrollment threshold, but its adjusted 90-day mortality benefit concentrated in the patients under 120. We're not extrapolating from a broader trial to a narrower patient; he sits inside the slice where the benefit was actually measured.
I take the trial seriously, but ACURASYS dates from 2010 and it's not the last word here. ROSE — the PETAL Network trial, a much larger multicenter study — tested early continuous cisatracurium paired with deep sedation against a light-sedation-first strategy using paralysis only as rescue, and found 90-day in-hospital mortality essentially identical: 42.5% against 42.8%. I'd be careful how that result gets described, though — the harm signal wasn't in mortality at all, it was in serious cardiovascular adverse events, fourteen against four, alongside less physical activity during the admission. ROSE also ran at a higher baseline PEEP than ACURASYS did, which is the design difference that actually separates them.
You're right that 118 sits below the threshold where ACURASYS's benefit concentrated — but ROSE enrolled that same band and didn't reproduce it. I'd rather optimize his sedation and reassess synchrony before committing to forty-eight hours of a drug that mutes every neurologic exam we'd otherwise be doing on him.
There's a version of tonight's actual decision that doesn't require either of you to be right about the broader ACURASYS-versus-ROSE question. He's being turned in the next hour, and the specific risk right now is desaturation or device dislodgement during the turn itself if he bucks against the ventilator mid-turn — that risk exists regardless of which 48-hour strategy eventually wins. A single cisatracurium bolus timed to the turn, with train-of-four monitoring so we're not layering an unmeasured, prolonged block on top of everything else, resolves the proning-specific problem without pre-committing either of you to forty-eight hours of continuous infusion tonight.
Agreed within minutes: a single cisatracurium bolus timed to the proning maneuver itself, train-of-four monitoring to confirm the block clears rather than accumulates, and a formal reassessment of ventilator synchrony once he's stable prone and sedation has been re-optimized.
Not agreed:
Whether to convert to the full 48-hour continuous ACURASYS infusion if dyssynchrony persists after proning. The critical care physician wants to commit early given the trial's mortality signal in exactly this severity band; the pulmonologist wants to see whether re-optimized sedation alone resolves the dyssynchrony first, given that ROSE found no benefit to routine paralysis in a comparably severe population managed on modern ventilation. Neither position was overruled — the question was simply deferred to the post-proning reassessment.